DMR Logo.png
Western Blotting Market Is Expected To Generate Revenue Of USD 2,620.2 Mn By 2033, At 6.8% CAGR: Dimension Market Research.
September 18, 2024 12:15 ET | Dimension Market Research
New York, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Overview The Global Western Blotting Market is expected to reach USD 1,455.4 million in 2024  which is further projected to grow up to USD 2,620.2...
cmi_logo.png
[Latest] Global Sanitary Pumps and Valves Market Size/Share Worth USD 3.1 Billion by 2033 at a 3.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
September 17, 2024 13:00 ET | Custom Market Insights
Austin, TX, USA, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Sanitary Pumps and Valves Market Size, Trends and Insights By Type...
Aclaris_Logo_CLR®.jpg
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
September 17, 2024 07:00 ET | Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Sanofi new_logo.jpg
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2024
September 16, 2024 12:44 ET | Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi new_logo.jpg
Sanofi: Information concerning the total number of voting rights and shares - August 2024
September 16, 2024 12:44 ET | Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
Saudi Arabian Pharmaceutical Market
Saudi Arabia $13.99 Bn Pharmaceutical Market Trends, Competition, Forecast & Opportunities, 2029F
September 16, 2024 10:46 ET | Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Saudi Arabia Pharmaceutical Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Indian Pharmaceutical Market
India Pharmaceutical Industry Research 2024: $105+ Billion Market Trends, Regional Insights, Competition, Forecasts and Opportunities, 2020-2030
September 11, 2024 11:50 ET | Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "India Pharmaceutical Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...
Regeneron Logo.jpg
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
September 11, 2024 01:04 ET | Regeneron Pharmaceuticals, Inc.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in...
Regeneron Logo.jpg
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024 00:59 ET | Regeneron Pharmaceuticals, Inc.
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is...
logo.jpg.jpg
ViaDerma Completes First Shipment of 500,000 Units to Nigeria
September 10, 2024 08:00 ET | ViaDerma, Inc.
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to...